Researchers studied KRAS mutant tumors in early passage colon tumor xenograft models from patients. They found that while the tumors did not respond to the epidermal growth factor receptor therapeutic antibody cetuximab, they were affected by anti-DLL4. The combination of anti-DLL4 and irinotecan decreased colon cancer stem cell frequency and promoted apoptosis in the tumor cells.
The researchers suggest targeting DLL4-Notch signaling to treat colorectal cancer patients with KRAS mutations.
Read the Cancer Research abstract.
Read more coverage on colon cancer research:
– Adenoma Detection Rate Associated With Risk of CRC
– Study: Method for Predicting Colon Cancer in Mice May Lead to Replacement for Colonoscopies
– University Hospitals-Case Western: Lack of Sleep Heightens Risk of CRC
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.